On November 24, 2025, Novo Nordisk announced top-line results from its phase 3 evoke and evoke+ trials, revealing that oral semaglutide did not show superiority over placebo in slowing progression of early-stage symptomatic Alzheimer’s disease, though it did improve certain disease-related biomarkers.
This outcome highlights the ongoing challenge of developing effective disease-modifying treatments for Alzheimer’s, underscoring both the scientific complexity and the significant unmet need in this therapeutic area.
We’ll explore how the lack of efficacy for semaglutide in Alzheimer’s may reshape Novo Nordisk’s longer-term growth prospects beyond its core metabolic franchise.
The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer’s.
Novo Nordisk’s investment story rests on the long-term expansion of its metabolic franchise, particularly with GLP-1 therapies like Ozempic and Wegovy, as well as the potential to diversify into new therapeutic areas. The recent setback in Alzheimer’s with oral semaglutide does not materially affect the key short-term catalyst: further volume growth and access for its core obesity and diabetes drugs, though it does illustrate the challenges and risks of R&D outside its main focus.
Of the recent announcements, the launch of the 9amHealth “No-Barriers Bundle” stands out, as it reinforces the trend of broadening access to branded GLP-1 medications like Wegovy. This type of initiative supports volume growth in obesity treatment, but also highlights intensifying efforts to make these medications accessible at lower prices, directly tying into both expanded adoption and pricing pressure risks.
However, against this positive momentum, investors should be aware of rising price erosion and how it might impact …
Read the full narrative on Novo Nordisk (it’s free!)
Novo Nordisk’s narrative projects DKK396.7 billion revenue and DKK142.5 billion earnings by 2028. This requires 8.3% yearly revenue growth and a DKK31.4 billion earnings increase from DKK111.1 billion currently.
Uncover how Novo Nordisk’s forecasts yield a DKK431.99 fair value, a 51% upside to its current price.
CPSE:NOVO B Community Fair Values as at Nov 2025
With 123 individual fair value estimates from the Simply Wall St Community ranging from DKK340 to DKK1,076, opinions on Novo Nordisk’s true worth vary widely. As competition increases and pricing pressures mount, understanding these different investor viewpoints may be essential when weighing the company’s outlook.
Explore 123 other fair value estimates on Novo Nordisk – why the stock might be worth just DKK340.00!
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com